Tatva Chintan Pharma Chem Reports Robust Q2 Turnaround with 99.2 Million Rupees Net Profit
Tatva Chintan Pharma posted a net profit of 99.2 million rupees in Q2, recovering from a 6.64 million rupees loss last year. Revenue grew 48.5% to 1.24 billion rupees. EBITDA increased to 222 million rupees with margin expanding to 17.99%. Half-year performance showed total income of 2,425.43 million rupees and net profit of 165.68 million rupees. The company appointed Ajesh Kumar Mohanan Pillai as CFO and KMP.

*this image is generated using AI for illustrative purposes only.
Tatva Chintan Pharma has reported a significant turnaround in its financial performance for the second quarter. The specialty chemicals manufacturer posted a net profit of 99.2 million rupees, marking a substantial recovery from a loss of 6.64 million rupees in the same period last year.
Revenue Growth
The company's revenue saw a notable increase, growing to 1.24 billion rupees from 835 million rupees year-over-year, representing a growth of approximately 48.5%.
Profitability Metrics
Tatva Chintan's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) surged to 222 million rupees, up from 56 million rupees in the corresponding quarter of the previous year. The EBITDA margin expanded significantly to 17.99% from 6.69%, indicating improved operational efficiency.
Financial Performance Overview
| Metric (in million rupees) | Q2 Current | Q2 Previous | YoY Change | 
|---|---|---|---|
| Revenue | 1,240.00 | 835.00 | +48.5% | 
| EBITDA | 222.00 | 56.00 | +296.4% | 
| Net Profit/(Loss) | 99.20 | (6.64) | N/A | 
| EBITDA Margin | 17.99% | 6.69% | +11.30 pts | 
Half-Year Performance
For the half-year ended September 30, Tatva Chintan reported:
- Total income: 2,425.43 million rupees
- Profit before tax: 227.64 million rupees
- Net profit: 165.68 million rupees
Balance Sheet Highlights
As of September 30, Tatva Chintan reported:
- Total assets: 9,077.40 million rupees
- Total equity: 7,543.89 million rupees
- Current assets: 2,964.43 million rupees
- Current liabilities: 1,519.53 million rupees
Corporate Updates
The Board of Directors approved the appointment of Mr. Ajesh Kumar Mohanan Pillai as the Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company, effective from October 31.
Tatva Chintan Pharma's robust quarterly performance reflects a strong recovery and improved operational efficiency. The company's ability to turn a loss into a significant profit, coupled with substantial revenue growth, indicates positive momentum in its business operations.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years | 
|---|---|---|---|---|---|
| +4.60% | +5.52% | +40.56% | +101.89% | +67.77% | -38.49% | 










































